- Addus HomeCare reported third quarter 2026 net income of US$28.59 million and diluted EPS from continuing operations of US$1.54, both above the prior year period, with nine month net income reaching US$81.27 million and diluted EPS of US$4.39.
- The earnings update, combined with upcoming conference participation by senior leadership, highlights how Addus HomeCare is pairing higher profitability with active investor communication on its home based care strategy.
- We will now look at how Addus HomeCare's stronger quarterly earnings profile could influence the broader investment narrative around the company.
Scan how Addus HomeCare's latest earnings stack up against a curated group of peers by reviewing the list of solid balance sheet and fundamentals (24 results) for potential home based care comparables with stronger financial footing.
Addus HomeCare Investment Narrative Recap
To hold Addus HomeCare, you need to believe the home based care model can keep funding, labor supply and service quality aligned. The analyst consensus Narrative on Simply Wall St centers on execution in personal care, technology and acquisitions. The latest quarter shows net income and EPS from continuing operations that keep this profitability story intact in the near term.
The key short term catalyst still sits in how reimbursement changes and acquired volumes translate into EBITDA and cash conversion. The biggest immediate risk remains pressure on Medicaid and Medicare rates, alongside wage inflation, which could squeeze margins even if headline earnings hold up.
The third quarter 2026 report is the clearest operational data point right now. Net income of US$28.59 million and diluted EPS from continuing operations of US$1.54 for the period, and US$81.27 million and US$4.39 for the nine months, provide more current visibility into how Addus HomeCare is handling wage, tax and reimbursement pressures described in earlier commentary.
Conference participation on November 17, 2026 adds another piece. With the Chairman and CEO and the CFO presenting at the Stephens event and hosting a webcast, investors get a timely check in on how management views Medicaid risk, labor costs and the integration of past acquisitions, all of which tie directly into the catalysts outlined in the earlier analyst consensus Narrative on Simply Wall St.
Addus HomeCare's narrative projects US$1.7b revenue and US$142.6 million earnings by 2029. This implies 5.2% yearly revenue growth and an earnings increase of about US$37.3 million from US$105.3 million today.
Uncover why Addus HomeCare's fair value indicates a 7% potential upside to its current price, which could narrow quickly.
Exploring Other Perspectives
One alternate view on Addus HomeCare leans hard into Medicaid risk. The lowest analysts already penciled in about US$1.7b revenue and US$158.1 million earnings for 2029 before this earnings beat. Those forecasts still came with a lower price target, which shows how sharply opinions can differ. Treat this quarter as a fresh data point that could reshape both stories.
Explore 3 other Addus HomeCare fair value estimates, including one that suggests as much as 30% downside from the current price.
Decide For Yourself
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
- A great starting point for your Addus HomeCare research is our analysis highlighting 4 key rewards that could impact your investment decision.
- See our latest analysis for Addus HomeCare. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Addus HomeCare's overall financial health at a glance.
Looking for more Addus HomeCare style investment ideas?
If you want to put Addus HomeCare in context, it helps to scan a wider field of opportunities and see which other businesses line up with the risk and return profile you prefer. The Simply Wall St Screener can help you do that in a structured way.
- If capital preservation sits high on your list, you may want to review companies identified as having steadier risk profiles through the 30 resilient stocks with low risk scores.
- If you care most about paying a fair price for strong fundamentals, compare Addus HomeCare with companies highlighted in the 32 high quality undervalued stocks and see how the quality and balance sheet metrics stack up.
- If you are hunting for less crowded ideas with solid financials, scan the 19 high quality undiscovered gems and build a shortlist for deeper research.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com